Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Growth (Status and Outlook) 2024-2030

Publication ID:

LPI02259093

Publication Date:

February 20, 2025

Pages:

119

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services market size is predicted to grow from US$ 483 million in 2024 to US$ 864 million in 2030; it is expected to grow at a CAGR of 10.2% from 2024 to 2030.
Proteolysis Targeting Chimeras (PROTACs) are a series of hetero-bifunctional molecules that hijack the body鈥檚 own natural disposal system to initiate selective degradation of the protein of interest (POI). PROTACs have the potential to overcome most of the limitations of small molecule inhibitors, and they offer several advantages of the traditional concepts of drug discovery.
United States market for Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services players cover WuXi AppTec, Syngene International Limited, Charles River Laboratories, Veranova, L.P., Aurigene Pharmaceutical Services Ltd, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
The 鈥淧roteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Industry Forecast鈥� looks at past sales and reviews total world Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services sales in 2023, providing a comprehensive analysis by region and market sector of projected Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services sales for 2024 through 2030. With Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services industry.
This Insight Report provides a comprehensive analysis of the global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services.
This report presents a comprehensive overview, market shares, and growth opportunities of Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services market by product type, application, key players and key regions and countries.
Segmentation by Type:
PROTACs Targeting Protein Kinases
PROTACs Targeting Nuclear Receptors
PROTACs Targeting BET Proteins
PROTACs Targeting Additional Protein
Segmentation by Application:
Targeted Protein Degradation
Drug Discovery
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
WuXi AppTec
Syngene International Limited
Charles River Laboratories
Veranova, L.P.
Aurigene Pharmaceutical Services Ltd
BOC Sciences
BPS Bioscience
Bio-Techne
Apeloa Pharmaceutical Co. Ltd.
Aganitha AI Inc.
Creative Biolabs

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size 2019-2030
2.1.2 Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services by Country/Region, 2019, 2023 & 2030
2.2 Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Segment by Type
2.2.1 PROTACs Targeting Protein Kinases
2.2.2 PROTACs Targeting Nuclear Receptors
2.2.3 PROTACs Targeting BET Proteins
2.2.4 PROTACs Targeting Additional Protein
2.3 Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size by Type
2.3.1 Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size Market Share by Type (2019-2024)
2.4 Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Segment by Application
2.4.1 Targeted Protein Degradation
2.4.2 Drug Discovery
2.4.3 Other
2.5 Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size by Application
2.5.1 Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size Market Share by Application (2019-2024)
3 Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size by Player
3.1 Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size Market Share by Player
3.1.1 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Revenue by Player (2019-2024)
3.1.2 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Revenue Market Share by Player (2019-2024)
3.2 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services by Region
4.1 Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size by Region (2019-2024)
4.2 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Annual Revenue by Country/Region (2019-2024)
4.3 Americas Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size Growth (2019-2024)
4.4 APAC Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size Growth (2019-2024)
4.5 Europe Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size Growth (2019-2024)
4.6 Middle East & Africa Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size Growth (2019-2024)
5 Americas
5.1 Americas Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size by Country (2019-2024)
5.2 Americas Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size by Type (2019-2024)
5.3 Americas Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size by Region (2019-2024)
6.2 APAC Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size by Type (2019-2024)
6.3 APAC Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size by Country (2019-2024)
7.2 Europe Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size by Type (2019-2024)
7.3 Europe Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services by Region (2019-2024)
8.2 Middle East & Africa Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size by Type (2019-2024)
8.3 Middle East & Africa Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Forecast
10.1 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast by Region (2025-2030)
10.1.1 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast by Region (2025-2030)
10.1.2 Americas Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast
10.1.3 APAC Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast
10.1.4 Europe Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast
10.1.5 Middle East & Africa Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast
10.2 Americas Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast by Country (2025-2030)
10.2.1 United States Market Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast
10.2.2 Canada Market Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast
10.2.3 Mexico Market Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast
10.2.4 Brazil Market Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast
10.3 APAC Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast by Region (2025-2030)
10.3.1 China Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Market Forecast
10.3.2 Japan Market Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast
10.3.3 Korea Market Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast
10.3.4 Southeast Asia Market Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast
10.3.5 India Market Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast
10.3.6 Australia Market Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast
10.4 Europe Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast by Country (2025-2030)
10.4.1 Germany Market Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast
10.4.2 France Market Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast
10.4.3 UK Market Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast
10.4.4 Italy Market Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast
10.4.5 Russia Market Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast
10.5 Middle East & Africa Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast by Region (2025-2030)
10.5.1 Egypt Market Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast
10.5.2 South Africa Market Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast
10.5.3 Israel Market Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast
10.5.4 Turkey Market Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast
10.6 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast by Type (2025-2030)
10.7 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast by Application (2025-2030)
10.7.1 GCC Countries Market Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecast
11 Key Players Analysis
11.1 WuXi AppTec
11.1.1 WuXi AppTec Company Information
11.1.2 WuXi AppTec Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Product Offered
11.1.3 WuXi AppTec Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 WuXi AppTec Main Business Overview
11.1.5 WuXi AppTec Latest Developments
11.2 Syngene International Limited
11.2.1 Syngene International Limited Company Information
11.2.2 Syngene International Limited Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Product Offered
11.2.3 Syngene International Limited Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Syngene International Limited Main Business Overview
11.2.5 Syngene International Limited Latest Developments
11.3 Charles River Laboratories
11.3.1 Charles River Laboratories Company Information
11.3.2 Charles River Laboratories Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Product Offered
11.3.3 Charles River Laboratories Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Charles River Laboratories Main Business Overview
11.3.5 Charles River Laboratories Latest Developments
11.4 Veranova, L.P.
11.4.1 Veranova, L.P. Company Information
11.4.2 Veranova, L.P. Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Product Offered
11.4.3 Veranova, L.P. Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Veranova, L.P. Main Business Overview
11.4.5 Veranova, L.P. Latest Developments
11.5 Aurigene Pharmaceutical Services Ltd
11.5.1 Aurigene Pharmaceutical Services Ltd Company Information
11.5.2 Aurigene Pharmaceutical Services Ltd Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Product Offered
11.5.3 Aurigene Pharmaceutical Services Ltd Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Aurigene Pharmaceutical Services Ltd Main Business Overview
11.5.5 Aurigene Pharmaceutical Services Ltd Latest Developments
11.6 BOC Sciences
11.6.1 BOC Sciences Company Information
11.6.2 BOC Sciences Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Product Offered
11.6.3 BOC Sciences Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 BOC Sciences Main Business Overview
11.6.5 BOC Sciences Latest Developments
11.7 BPS Bioscience
11.7.1 BPS Bioscience Company Information
11.7.2 BPS Bioscience Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Product Offered
11.7.3 BPS Bioscience Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 BPS Bioscience Main Business Overview
11.7.5 BPS Bioscience Latest Developments
11.8 Bio-Techne
11.8.1 Bio-Techne Company Information
11.8.2 Bio-Techne Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Product Offered
11.8.3 Bio-Techne Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Bio-Techne Main Business Overview
11.8.5 Bio-Techne Latest Developments
11.9 Apeloa Pharmaceutical Co. Ltd.
11.9.1 Apeloa Pharmaceutical Co. Ltd. Company Information
11.9.2 Apeloa Pharmaceutical Co. Ltd. Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Product Offered
11.9.3 Apeloa Pharmaceutical Co. Ltd. Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Apeloa Pharmaceutical Co. Ltd. Main Business Overview
11.9.5 Apeloa Pharmaceutical Co. Ltd. Latest Developments
11.10 Aganitha AI Inc.
11.10.1 Aganitha AI Inc. Company Information
11.10.2 Aganitha AI Inc. Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Product Offered
11.10.3 Aganitha AI Inc. Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Aganitha AI Inc. Main Business Overview
11.10.5 Aganitha AI Inc. Latest Developments
11.11 Creative Biolabs
11.11.1 Creative Biolabs Company Information
11.11.2 Creative Biolabs Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Product Offered
11.11.3 Creative Biolabs Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Creative Biolabs Main Business Overview
11.11.5 Creative Biolabs Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂